ArticleInternational journal of women's health2026
Cost-Effectiveness of Culmerciclib Plus Fulvestrant for Previously Treated HR-Positive/HER2-Negative Advanced Breast Cancer in China: An Integrated GBD 2023 Analysis.
Feng Xuan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.